SciClone Pharmaceuticals (Holdings) Future Growth

How is SciClone Pharmaceuticals (Holdings) forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

-1.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

SEHK:6600 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	3,416	791	482	568	2
12/31/2023	3,085	963	610	846	3
6/30/2022	2,662	833	1,226	1,245	N/A
3/31/2022	2,590	878	1,032	1,137	N/A
12/31/2021	2,518	923	839	1,029	N/A
9/30/2021	2,259	837	506	840	N/A
6/30/2021	2,089	779	358	724	N/A
3/31/2021	2,004	766	435	853	N/A
12/31/2020	1,919	754	512	981	N/A
9/30/2020	2,001	817	657	974	N/A
12/31/2019	1,708	615	999	1,032	N/A
12/31/2018	1,409	535	143	167	N/A
12/31/2017	1,213	20	143	154	N/A
6/30/2017	1,166	294	234	242	N/A
3/31/2017	1,146	258	183	187	N/A
12/31/2016	1,112	213	235	240	N/A
9/30/2016	1,060	246	215	221	N/A
6/30/2016	1,072	257	226	231	N/A
3/31/2016	1,034	183	N/A	214	N/A

Earnings vs Savings Rate: 6600's earnings are forecast to decline over the next 3 years (-1.3% per year).

Earnings vs Market: 6600's earnings are forecast to decline over the next 3 years (-1.3% per year).

High Growth Earnings: 6600's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 6600's revenue (9.8% per year) is forecast to grow faster than the Hong Kong market (9.6% per year).

High Growth Revenue: 6600's revenue (9.8% per year) is forecast to grow slower than 20% per year.

Future ROE: 6600's Return on Equity is forecast to be high in 3 years time (23.6%)